Randomized study as second-line chemotherapy in mUC patients between gemcitabine and docetaxel regimen and pembrolizumab.
Phase 3
- Conditions
- metastatic urothelial carcinoma patients after treated first-line cisplatin based chemotherapy
- Registration Number
- JPRN-UMIN000032805
- Lead Sponsor
- Department of Nephro-urology, Nagoya City University Graduate School of Medical Sciences.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
1. allergy of gemcitabine, docetaxel, pembrolizumab patients. 2. interstitial pneumoniae, performed external radiation therapy in chest 3. sign of bacterial of viral infection patients. 4. pregnant or lactational patients 5. other cancer
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method progression free survival
- Secondary Outcome Measures
Name Time Method adverse events, overall survival, response to treatment, QOL after 2 cycles of treatment